Wedam, S., Narayan, P., Gittleman, H., Cheng, J., Bhatnagar, V., Sabit, H., Price, L. S., Rahman, N. A., Chiu, H., Biel, N., Ricks, T., Fiero, M., Tang, S., Osgood, C., Pierce, W., Pazdur, R., Kluetz, P. G., Amiri-Kordestani, L. (2025). US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant,
            <i>PIK3CA</i>
            -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00663